Thrombosis and COVID-19 pneumonia: the clot thickens!

At the end of last year, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulted in an acute respiratory illness epidemic in Wuhan, China [1, 2]. The World Health Organization (WHO) termed this illness coronavirus disease 2019 (COVID-19). The coronavirus family have been shown to enter cells through binding angiotensin-converting enzyme 2 (ACE-2), found mainly on alveolar epithelium and endothelium. Activation of endothelial cells is thought to be the primary driver for the increasingly recognised complication of thrombosis. Pulmonary thrombosis appears to be common in COVID-19 pneumonia and takes two forms, proximal pulmonary emboli and/or distal thrombosis. The possible mechanisms and clinical implications are discussed. https://bit.ly/372Xdhw

[1]  R. Favory,et al.  Pulmonary Embolism in Patients With COVID-19 , 2020, Circulation.

[2]  M. Humbert,et al.  Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? , 2020, European Respiratory Journal.

[3]  M. Thomeer,et al.  Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? , 2020, European Respiratory Journal.

[4]  M. Revel,et al.  Pulmonary embolism in patients with COVID-19 pneumonia , 2020, European Respiratory Journal.

[5]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[6]  G. Mahé,et al.  Emergence of institutional antithrombotic protocols for coronavirus 2019 , 2020, Research and Practice in Thrombosis and Haemostasis.

[7]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[8]  J. Connors,et al.  COVID-19 and its implications for thrombosis and anticoagulation , 2020, Blood.

[9]  R. Woods,et al.  Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.

[10]  C. Roy,et al.  Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels , 2020, Radiology.

[11]  Nils Kucher,et al.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.

[12]  M. Ramakers,et al.  High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[13]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[14]  Gang Wang,et al.  Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 , 2020, Military Medical Research.

[15]  L. Beenen,et al.  Incidence of venous thromboembolism in hospitalized patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[16]  G. Grasselli,et al.  Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis , 2020, Journal of Thrombosis and Haemostasis.

[17]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[18]  Yutao Guo,et al.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.

[19]  David Berlin,et al.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.

[20]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[21]  Feng Wang,et al.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[22]  W. Liang,et al.  Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 , 2020, The Lancet Haematology.

[23]  R. McIntyre,et al.  Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series , 2020, Journal of Thrombosis and Haemostasis.

[24]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[25]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[26]  Zhaohui Zheng,et al.  SARS-CoV-2 invades host cells via a novel route: CD147-spike protein , 2020, bioRxiv.

[27]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[28]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[29]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[30]  N. Gupta,et al.  The stimulation of thrombosis by hypoxia. , 2019, Thrombosis research.

[31]  R. Pendleton,et al.  VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. , 2015, Chest.

[32]  G. Ferretti,et al.  Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis , 2015, Critical Care.

[33]  M. Huisman,et al.  Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review , 2014, European Respiratory Journal.

[34]  W. Travis,et al.  Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. , 2004, Archives of pathology & laboratory medicine.

[35]  Arul Earnest,et al.  Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. , 2003, JAMA.

[36]  J. Heitman,et al.  Dismantling the Cryptococcus coat: Response from D'Souza and Heitman , 2001 .

[37]  B. Cookson,et al.  Pro-inflammatory programmed cell death. , 2001, Trends in microbiology.

[38]  W. Kisiel,et al.  Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. , 1999, Arteriosclerosis, thrombosis, and vascular biology.